2,4-Dichloropyrimidine | CAS:3934-20-1

We serve 2,4-Dichloropyrimidine CAS:3934-20-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4-Dichloropyrimidine

Chemical Name:2,4-Dichloropyrimidine
CAS.NO:3934-20-1
Synonyms:2,4-dichloro-pyrimidine
2-Chloropyrimidin-4-yl chloride
2,4-Dichlorpyrimidin
Pyrimidine, 2,4-dichloro-
Molecular Formula:C4H2Cl2N2
Molecular Weight:148.97800
 
Physical and Chemical Properties:
Density:1.493
Melting point:60-61ºC
Boiling point:101ºC
Flash point:104.3±5.4ºC
Index of Refraction:1.559
 
Specification:
Appearance:Pale yellow or offwhite crystalline
Assay(HPLC):≥98.0%
Moisture:≤0.2%
Residue on ignition:≤0.3%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of minoxidil.



Contact us for information like 2,4-dichloro-pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Dichloropyrimidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrimidine, 2,4-dichloro- Use and application,Pyrimidine, 2,4-dichloro- technical grade,usp/ep/jp grade.


Related News: In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.2,3-dihydrobenzofuran manufacturer Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.2,4-Difluorobenzonitrile supplier At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content.2,4-Dichloropyridine vendor The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.